Clinical Trials Sponsored by Bexion Pharmaceuticals, Inc.

Total 5375 results

Lexicon Pharmaceuticals

Completed

DDI Study With Multiple-dose LX4211 and Single Dose Digoxin

Healthy

United States
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Lexicon Pharmaceuticals

Completed

A Thorough QT Study of Telotristat Etiprate

QT Interval

United States
Lexicon Pharmaceuticals

Completed

A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

Drug Interactions

United States
Lexicon Pharmaceuticals

Completed

An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

Drug Interactions

United States
Alexion Pharmaceuticals

Terminated

Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Czech Republic, Italy, Poland, United Kingdom
Lexicon Pharmaceuticals

Completed

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

Healthy

United States
Lexicon Pharmaceuticals

Completed

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

Healthy

United States
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) (STEC-HUS)

Shiga-like Toxin-producing Escherichia Coli

Germany
Lexicon Pharmaceuticals

Completed

Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Bexion Pharmaceuticals, Inc.
CTI Clinical Trial and Consulting Services

Terminated

A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors (KOURAGE)

Neoplasms

United States
Lexicon Pharmaceuticals

Completed

Efficacy, Safety, and PK of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1)

Diabetes | Diabetic Peripheral Neuropathy

United States
Alexion Pharmaceuticals

Terminated

An Efficacy and Safety Study of Ravulizumab in ALS Participants

Amyotrophic Lateral Sclerosis | ALS

United States, Spain, Italy, Belgium, Canada, Switzerland, Australia, Germany, Denmark, Israel, Sweden, France, Ireland, United Kingdom, Japan, Netherlands, Poland
Alexion Pharmaceuticals

Completed

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease

United Kingdom, United States
Alexion Pharmaceuticals

Completed

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

Hong Kong, Korea, Republic of, United States, Croatia, Australia, Canada, Malaysia, Japan, Italy, Turkey, Spain, Taiwan, Argentina, Colombia, Czechia, Denmark, Germany, Russian Federation, Thailand, United Kingdom
Alexion Pharmaceuticals

Completed

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH

Korea, Republic of, Australia
Alexion Pharmaceuticals

Withdrawn

Study in Adult and Pediatric Patients With HSCT-TMA

Thrombotic Microangiopathies | Stem Cell Transplant Complications

United States
Alexion Pharmaceuticals

Withdrawn

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States
Alexion Pharmaceuticals

No longer available

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

COVID-19 | Pneumonia, Viral | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

United States, France
Alexion Pharmaceuticals

Completed

Study of Danicopan in Participants of Japanese Descent

Healthy

Australia
Alexion Pharmaceuticals

Withdrawn

ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

United States
Alexion Pharmaceuticals

Terminated

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

Warm Autoimmune Hemolytic Anemia

United States, Jordan
Alexion Pharmaceuticals

Terminated

A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Pemphigus | Pemphigus Vulgaris | Pemphigus Foliaceus

United States
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency

Spain, Germany, Italy, United States, Croatia, Canada, Russian Federation, Denmark, United Kingdom, Belgium, Mexico, Australia, Netherlands, Brazil, Turkey
Alexion Pharmaceuticals

Terminated

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency

United Kingdom, Finland, United States, Italy
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms (TELEPATH)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom
Alexion Pharmaceuticals

Completed

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

Refractory Generalized Myasthenia Gravis

Korea, Republic of, United States, Spain, Canada, Netherlands, Belgium, Czechia, Denmark, Italy, Australia, Finland, Turkey, Germany, Greece, Brazil, Argentina, Japan, United Kingdom, Hungary, France, Sweden
Alexion Pharmaceuticals

Completed

Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, France, United Kingdom, Canada, Netherlands, Russian Federation, Turkey, Australia
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, Canada, United Arab Emirates, United Kingdom
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)

Hypophosphatasia

United States, Canada
Alexion Pharmaceuticals

Completed

Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)

Hypophosphatasia

United States, United Arab Emirates, United Kingdom
Alexion Pharmaceuticals

Completed

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

Wolman Disease | Lysosomal Acid Lipase Deficiency

United Kingdom, France, United States, Egypt, Ireland
Alexion Pharmaceuticals

Terminated

Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB

MPS IIIB (Sanfilippo B Syndrome)

Spain, United States, Brazil, United Kingdom, Portugal, Italy
Alexion Pharmaceuticals

Completed

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency | LAL-Deficiency | Cholesterol Ester Storage Disease (CESD)

France, United Kingdom, United States, Canada, Czechia
Alexion Pharmaceuticals

Terminated

A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously (CL01-T)

Mucopolysaccharidosis III, Type B (MPS IIIB) | Sanfilippo B

United Kingdom
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

Paroxysmal Nocturnal Hemoglobinuria
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate for Carcinoid Syndrome Therapy (TELECAST)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Spain, Sweden, United Kingdom, Netherlands
Alexion Pharmaceuticals

Terminated

Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

Antibody Mediated Rejection

United States, Germany, Italy, France, United Kingdom, Spain, Sweden, Australia, Netherlands, Norway
Alexion Pharmaceuticals

Terminated

Screening for Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency

United States
Alexion Pharmaceuticals

Completed

Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan

Hypophosphatasia
Alexion Pharmaceuticals

Terminated

aHUS Observational Long Term Follow-Up (LTFU)

Atypical Hemolytic Uremic Syndrome

France, Canada, United States, Belgium, Italy, United Kingdom, Netherlands, Australia, Austria, Germany, Sweden, Switzerland
Alexion Pharmaceuticals

Completed

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Coronary Artery Bypass Graft | Cardio-pulmonary Bypass

United States, Canada
Alexion Pharmaceuticals

Completed

Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging

MPS IIIB (Sanfilippo B Syndrome)

United Kingdom
Alexion Pharmaceuticals

No longer available

An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency
Lexicon Pharmaceuticals

Unknown

Oral Contraceptive DDI Study

Healthy

United States
Alexion Pharmaceuticals

Completed

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS (aHUS)

Atypical Hemolytic Uremic Syndrome

France, United States, Austria, Germany, United Kingdom
Alexion Pharmaceuticals

Completed

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) (aHUS)

Atypical Hemolytic Uremic Syndrome

Canada, United Kingdom, France, Germany, Sweden, Netherlands, Italy
Alexion Pharmaceuticals

Completed

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome (aHUS)

Atypical Hemolytic-Uremic Syndrome

United Kingdom, Belgium, United States, Germany, Italy, France, Netherlands, Australia, Canada
Lexicon Pharmaceuticals

Completed

An Open-Label Food Effect Study of Telotristat Etiprate

Healthy

United States
Alexion Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects

Healthy Subjects

United States

Clinical Trials Sponsored by Bexion Pharmaceuticals, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations